About Lenalidomide (Form A) API
Therapeutic Category Anti-Cancer/ Oncology
CAS Number
191732-72-6
API Technology
High Potent
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
Russia DMF, Brazil DMF, USDMF, EUDMF, Canada DMF, China DMF, Japan DMF
Mechanism of Action
Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro.
Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including MM. Immunomodulatory properties of lenalidomide include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In MM cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
Indication
REVLIMID is a thalidomide analogue indicated for the treatment of patients with:
- Multiple myeloma (MM), in combination with dexamethasone
- MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
- Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
- Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
Limitations of Use:
- REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
FAQs
Check with your doctor right away if you have anxiety, chest pain, fainting, a fast heartbeat, trouble breathing, or pain, redness, or swelling in the arm or leg.
-
Lenalidomide is used to treat anemia (low red blood cells) in patients with a certain type of myelodysplastic syndrome (MDS).
-
Lenalidomide belongs to class I and III of BCS classification.
-
The DMFs are available in the US, Brazil, Europe, Canada and Russia.
-
Lenalidomide should be stored at 20 °C - 25 °C (68 °F - 77 °F).
-
Lenalidomide is available in capsule form with 2.5, 5, 10, 15, 20 , 25 mg strengths.